SCHEMBL4350095

SCHEMBL4350095

O=C(NCCc1ccccc1)N(S)c1cc(Br)cc(F)c1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.46
MEN1 O00255 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
ALOX12 P18054 1/20 0.46
CYP2C19 P33261 1/20 0.46
KMT2A Q03164 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
NPC1 O15118 6/20 0.44
RAB9A P51151 6/20 0.44
PLAAT5 Q96KN8 3/20 0.40
PLAAT4 Q9UL19 3/20 0.40
PLAAT3 P53816 2/20 0.40
PLAAT2 Q9NWW9 2/20 0.40
HDAC2 Q92769 2/20 0.40
HDAC8 Q9BY41 2/20 0.40
HDAC6 Q9UBN7 2/20 0.40
HDAC3 O15379 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4355899 0.84 RAB9A (0.53) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL4349030 0.81 RAB9A (0.49) MEN1KMT2ANPC1RAB9APLAAT5
SCHEMBL4346354 0.81 RAB9A (0.46) MEN1CYP1A2CYP2D6CYP2C9ALOX12
SCHEMBL4348538 0.79 NPC1 (0.47) MAPTMEN1ALOX12KMT2ASMN1; SMN2
SCHEMBL4349401 0.78 MGLL (0.38) MEN1CYP3A4CYP2D6KMT2ASMN1; SMN2
SCHEMBL4350012 0.78 HDAC2 (0.47) NPC1RAB9APLAAT5PLAAT4HDAC2
SCHEMBL4351442 0.77 CA1 (0.45) MAPTMEN1ALOX12KMT2ASMN1; SMN2
SCHEMBL4355452 0.77 CA1 (0.43) MAPTMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL4345602 0.77 GAA (0.41) KMT2ASMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL4345936 0.76 MEN1 (0.53) MAPTMEN1CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
WO-2004030664-A2 NEW COMPOUNDS FOR THE INHIBITION OF UNDESIRED CELL PROLIFERATION AND USE THEREOF JERINI AG (DE) 2004-04-15 WO claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 MAPT 4439/4885MEN1 2168/4885CYP1A2 215/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 MAPT 4184/4885MEN1 3901/4885CYP1A2 147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.